|Segment||Equity: Global Ex-U.S. - Total Market Growth||Inverse Equity: U.S. Biotech|
|Management Style||passive (index-based)||passive (index-based)|
|Underlying Index||--||NASDAQ Biotechnology Index|
The Fund seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index and the BNY Mellon Classic ADR Index. The Fund selects a portfolio of U.S. traded securities of non-U.S. organizations, most often American Depositary Receipts (ADRs), included in the BNY Mellon Classic ADR Index.
AADR performance & returns
Top 10 Holdings (38.80% of Total Assets)
|ASML Holding NV ADR||ASML||5.52%|
|BioNTech SE ADR||BNTX.DE||4.57%|
|LVMH Moet Hennessy Louis Vuitton SE ADR||LVMUY.PA||4.16%|
|Himax Technologies Inc ADR||HIMX||3.79%|
|Sibanye Stillwater Ltd ADR||SBSW.JO||3.64%|
|Logitech International SA||LOGN||3.51%|
|Cemex SAB de CV ADR||CX.MX||3.22%|
|Embraer SA ADR||ERJ.SA||3.06%|
AADR prosNone that we could think of.
AADR consNone that we could think of.
Other relevant AADR comparisons
You may also want to check out the following AADR comparisons that investors often look for on Finny
The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) inverse (opposite) of the daily performance of the NASDAQ Biotechnology Index.
BIS performance & returns
Top 10 Holdings (199.98% of Total Assets)
|Nasdaq Biotechnology Index Swap Societe Generale||N/A||62.16%|
|Nasdaq Biotechnology Index Swap Ubs Ag||N/A||61.92%|
|Nasdaq Biotechnology Index Swap Bank Of America Na||N/A||57.92%|
|Nasdaq Biotechnology Index Swap Citibank Na||N/A||14.79%|
|Nasdaq Biotechnology Index Swap Morgan Stanley & Co. International Plc||N/A||3.19%|
BIS prosNone that we could think of.
BIS consNone that we could think of.
Other relevant BIS comparisons
You may also want to check out the following BIS comparisons that investors often look for on Finny